---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001677"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T12:14:41.978286+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Teva Q3 revenue up 7% to $3.9B, raises FY revenue guidance to $15.1-$15.5B

## Summary
- Revenue $3.85B (+7% YoY); GAAP EPS $0.07, non-GAAP EPS $0.60.
- Raised 2023 revenue outlook to $15.1-$15.5B from $15.0-$15.4B; reaffirms non-GAAP EPS $2.25-$2.55.
- AUSTEDO and AJOVY drove growth; global generics revenues increased across all segments.
- Entered exclusive collaboration with Sanofi on Anti TL1-A (TEV-'574) in October 2023.
- Appointed Dr. R. Ananthanarayanan as CEO of Teva api; olanzapine LAI Phase 3 results now H2 2024.

## SEC filing metadata
- accession: 0001157523-23-001677
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000115752323001677/0001157523-23-001677-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000115752323001677/a53780340.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001677
- JSON: https://secwatch.observer/filing/0001157523-23-001677.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001677.txt

## Key facts
- Earnings Releases
  TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended September 30, 2023 results: revenue $3.9 billion, EPS GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.60. Guidance raised.
  - Period: the quarter ended September 30, 2023
  - Revenue: $3.9 billion
  - EPS: GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.60
  - Guidance: raised
  - Result: reported results
  source text: Global revenues of $3.9 billion, reflect an increase of 7% from the third quarter of 2022 Increased revenues reflect sustained growth of AUSTEDO ® , AJOVY ® and global generics business: Growth of AUSTEDO in North America Growth of AJOVY globally Stable and sustainable generics business in the U.S.; continued growth in Europe and International Markets GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.60
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000115752323001677/0001157523-23-001677-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.